A Phase 1/2, Open-Label Safety and Tolerability Study of INCB057643 in Subjects With Advanced Malignancies

Investigator: Maen Abdelrahim, MD

Study Coordinator: Karen Woodard

Status: Enrolling

ClinicalTrials.gov Number: NCT02711137

Phone: 713.441.4332

Protocol Number: Pro00015047


This is an open-label, dose-escalation/dose-expansion study of INCB057643 in subjects with advanced malignancies. Part 1 will determine the maximum tolerated dose of INCB057643 and/or a tolerated dose that demonstrates sufficient pharmacologic activity. Part 2 will further evaluate the safety, preliminary efficacy, PK, and PD of the dose(s) selected in Part 1 in select tumor types.
More to Explore